Potential therapeutic role for statins in respiratory disease

Thorax

Volumn 61, Issue 8, 2006, Pages 729-734

  Hothersall, E ^a   McSharry, C ^a   Thomson, N C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CELL ADHESION MOLECULE; CERIVASTATIN; CHEMOKINE; CHOLESTEROL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONOLACTONE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE LUNG INJURY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; EMPHYSEMA; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LIPID RAFT; LUNG; LUNG FIBROSIS; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG DISEASES; RESPIRATORY SYSTEM AGENTS;

EID: 33747079023     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.057976     Document Type: Review

References (99)

1. Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Group. N Engl J Med 1995;333:1301-7.
4. Briel M, Studer M, Glass TR, et al. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004;117:596-606.
5. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-9.
6. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
7. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
8. Albert MA, Danielson E, Rifai N, et al. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation, JAMA 2001;286:64-70.
9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
10. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
11. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
12. Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001;116:S108-15.
13. Ikeda U, Shimada K. Statins and monocytes. Lancet 1999;353:2070.
14. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokinesin patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
15. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
16. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
17. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis - as good as it gets? N Engl J Med 2005;352:73-5.
18. Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004;172:1273-86.
19. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
20. Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb Haemost 2003;90:607-10.
21. Kimura M, Kurose I, Russel J, et al. Effects of fluvastatin on leucocyte-endothelial cell adhesion in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 1997;17:e1521-6.
22. Scalia R, Gooszen ME, Jones SP, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects on apolipoprotein E-deficient mice. Circulation 2001;103:2598-603.
23. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leucocyte-endothelial cell interactions and protects agains inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999;19:2894-900.
24. Rice JB, Stoll LL, Li WG, et al. Low-level endotoxin induces potent inflammatory activation of human blood vessels: Inhibition by statins. Arterioscler Thromb Vasc Biol 2003;23:1576-82.
25. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004;78:12062-5.
26. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001;89:415-21.
27. Martinez-Gonzalez J, Alfon J, Boerrozpe M, et al. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001;159:27-33.
28. Ikeda U, Shimada K. Statins and C-reactive protein. Lancet 1999;353:1274-5.
29. Inoue I, Gotto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 2000;67:863-76.
30. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res 2002;51:58-62.
31. Seeger H, Mueck AO, Lippert TH. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Int J Clin Pharmacol Ther 2000;38:270-2.
32. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
33. Newton CJ, Ran G, Xie YX, et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002;174:7-16.
34. van de Donk NWCJ, Kamphuis MMJ, van Kessel B, et al. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003;102:3354-62.
35. Rudich SM, Mongini PKA, Perez RV, et al. HMG-CoA reducatse inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc 1998;30:992-5.
36. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991;266:12216-22.
37. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003;93:948-56.
38. Brown RD, Ambler SK, Mitchell MD, et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Ann Rev Pharmacol Toxicol 2005;45:657-87.
39. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
40. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
41. Aviram M, Rosenblat M, Bisgaier CL, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998;138:271-80.
42. Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl conenzyme A reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 1998;361:143-9.
43. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5.
44. Girona J, La Ville AE, Sola R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-51.
45. Lawman S, Mauri C, Jury EC, et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004;173:7641-6.
46. Choi M, Rolle S, Rane M, et al. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 2003;63:96-106.
47. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
48. Gegg ME, Harry R, Hankey D, et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J Immunol 2005;174:2327-35.
49. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
50. Kiener PA, Davis PM, Murray JL, et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001;1:105-18.
51. Knapp AC, Huang J, Starling G, et al. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000;152:217-27.
52. Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NFκB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003;41:397-401.
53. Takahashi HK, Mori S, Iwagaki H, et al. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005;77:400-7.
54. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-4.
55. Wagner AH, Schwabe O, Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002;136:143-9.
56. Fehr T, Kahlert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004;175:83-90.
57. Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci 2003;92:7-12.
58. Watkins AD, Hatfield CA, Fidler SF, et al. Phenotypic analysis of airway eosinophils and lymphocytes in a Th-2-driven murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1996;15:20-34.
59. Watanabe T, Fan J. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol 1998;66:S45-53.
60. Winn M, Reilly EB, Liu G, et al. Discovery of novel p-arylthio cinnamides as antagonists of leucocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide. J Med Chem 2001;44:4393-403.
61. Gauvreau GM, Becker AB, Boulet LP, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003;112:331-8.
62. Hayden JM, Swartfiguer J, Szelinger S, et al. Lysophosphatidylcholine stimulation of alveolar epithelial cell interleukin-8 production and neutrophil chemotaxis is inhibited by statin treatment. Proc Am Thor Soc 2005;2:A72.
63. Luo F. Simvastatin induces eosinophil apoptosis in vitro. Chest 2004;126:721S.
64. Bureau F, Seumois G, Jaspar F, et al. CD40 engagements enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: possible involvement in allergic inflammation. J Allergy Clin Immunol 2002;110:443-9.
65. Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005;171:606-15.
66. Morimoto K, Janssen WJ, Fessier MB, et al. HMG Co-A reductase inhibitors (statins) enhance clearance of apoptotic cells in vitro and in vivo. Proc Am Thor Soc 2005;2:A902.
67. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998;17:335-40.
68. Wei H, Zhang J, Xiao W, et al. Involvement of human natural killer cells in asthma pathogenesis: natural killer 2 cells in type 2 cytokine predominance. J Allergy Clin Immunol 2005;115:841-7.
69. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604.
70. Takeda N, Kume H, Ito S, et al. Rho is involved in the inhibitory effects of simvastatin on proliferation of human airway smooth muscle cells (abstract). Eur Respir J, 2005;26,(Suppl 49):223s.
71. Qin J, Zhang Z, Liu J, et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003;64:565-71.
72. Lee J-H, Lee D-S, Kim E-K, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93.
73. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-9.
74. Bellosta S, Via D, Canavesi P, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
75. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000;36:325-9.
76. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
77. Lazzerini PE, Capecchi PL, Nerucci F, et al. Simvastatin reduces MMP-3 level in interleukin-1β stimulated human chondrocyte culture. Ann Rheum Dis 2004;63:867-9.
78. Holt PG, McCaubus C, Stumbles PA, et al. The role of allergy in the development of asthma. Nature 1999;402:B12-7.
79. Robinson DS, Hamid Q, Ying S, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
80. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma. Pharmacol Rev 1998;50:515-96.
81. Hansen G, Berry G, DeKruyff RH, et al. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999;103:175-83.
82. Randolph DA, Carruthers CJ, Szabo SJ, et al. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999;162:2375-83.
83. Cohn L, Homer RJ, Niu N, et al. T helper 1 cells and interferon χ regulate allergic airway inflammation and mucus production. J Exp Med 1999;190:1309-17.
84. McKay A, Leung BP, McInnes IB, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-8.
85. Yeh YF, Huang SL. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci 2004;11:599-606.
86. Lee J-H, Lee D-S, Kim E-K, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93.
87. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004;24:822-33.
88. Takahashi S, Nakamura H, Furuuchi M, et al. Simvastatin suppresses the development of elastase-induced emphysema in mice (abstract). Proc Am Thor Soc 2005;2:A135.
89. Carlin CM, Peacock AJ, Welsh DJ. Statins inhibit hypoxic proliferation of pulmonary artery fibroblasts: potential for the treatment of pulmonary hypertension (abstract). Thorax 2005;60(Suppl II):ii4.
90. Stark WWJ, Blaskovich MA, Johnson BA, et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol 1998;275:L55-63.
91. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285:H938-45.
92. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5.
93. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005;127:1446-52.
94. Khalil N, Bereznay O, Sporn M, et al. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 1989;170:727-37.
95. Watts KL, Sampson EM, Schultz GS, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005;32:290-300.
96. Nadrous HF, Ryu JH, Douglas WW, et al. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004;126:438-46.
97. Jacobson JR, Barnard JW, Grigiryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005;288:L1026-32.
98. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82-9.
99. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003;167:1271-8.